|Phenotype||CKDi25 cases defined as >25% eGFRcrea decline during follow-up together with a movement from eGFRcrea≥60 mL/min/1.73m^2 at baseline to eGFR<60 mL/min/1.73m^2 at follow up compared to CKDi25 controls defined as eGFRcrea≥60 mL/min/1.73m^2. High risk groups had 8-14 adverse alleles. Low risk groups had 0-5 adverse alleles.|
448 cases (3.92%)
|Number of Cohort(s)||3|
|Cohort Short Name||Cohort Full Name||Previous/other/additional names (e.g. sub-cohorts)|
|KORA||Cooperative Health Research in the Region of Augsburg||KORA F3, KORA F4, KORA S3, KORA S4|
87.61% overlap between the CKDi25 GWAS cohort and this dataset.